Introduction and background
Epilepsia partialis continua (EPC) is defined as a syndrome of ''spontaneous regular or irregular clonic muscle twitching of cerebral origin, sometimes aggravated by action or sensory stimuli, confined to one part of the body, and continuing for a period of hours, days or weeks'' 1 and ''recurring at intervals of no more than ten seconds''. 2 EPC is conceptualized as a special form of focal status epilepticus 3 and in western countries, when beginning in adult life, it is usually secondary to cerebral vascular disorders or neoplasms, whereas the most common cause of EPC in childhood is Rasmussen's encephalitis. 4, 5 Prognosis of EPC with regard to neurological outcome and control of continuous jerking depends largely on the underlying etiology. While EPC due to Rasmussen's encephalitis has been shown to be highly resistant to any kind of medical therapy, drug therapy may be successful in adult patients where EPC is often caused by local, non-progressive lesions. Even in those patients, however, medical therapy of EPC remains a challenge and in most cases, control of twitching can only be achieved by polytherapy with various combinations of intravenously administered antiepileptic drugs, including diazepam, pentothal sodium and valproate. 6, 7 Here, we report for the first time the instantaneous benefit of levetiracetam treatment administered intravenously in EPC.
Materials and methods/patient
A 60-year-old female patient presented with continuous jerking of the right foot and hallux persisting for more than two days. A left temporoparietal oligodendroglioma (see Fig. 1 ) had been diagnosed 10 years ago. Since then she has been treated with seedimplantation, neurosurgical resection and temozolamide therapy. On admission, she had no oncological therapy at all since more than one year and there were no signs of tumor progression. She suffered from a slight amnestic aphasia, an incomplete Gerstmann's syndrome with agraphia and acalculia and occasional focal epileptic seizures with speech arrest in addition to the continuous jerking of her right foot and hallux. Her anticonvulsive regimen on admission consisted of a daily dose of 1000 mg levetiracetam and 1200 mg oxcarbazepine. Serum concentration of levetiracetam on admission was 25.4 mg/l (normal range 10-30 mg/l). The last seizure dated back more than three months.
The reported episode began two days before admission with sudden onset of speech arrest and twitching of the right leg, foot and toe. Aphasia and twitching of the right leg decreased after sublingual application of 2.5 mg lorazepam and completely ceased after oral administration of 10 mg diazepam through her husband and 10 mg diazepam intravenously through the emergency physician. However, jerking of the right foot and toe persisted for more than two days and led to admission to our department. The right-handed patient presented fully awake with continuous irregular myoclonic jerks of the right foot but mainly the hallux without any further neurological deficit. The jerking worsened during movement and made her gait unsteady. The ictal EEG (see Fig. 2 ) recording showed a focal slowing with recurrent focal spikes and sharp waves in the left parietoocciptal region. On admission, 2 mg lorazepam were given intravenously without any change of jerking. An intolerance against phenytoin was known from the medical history. The patient's husband reported on elevated liver enzymes in the previous history. Thus, we abandoned the use of valproate. We administered 2000 mg A B S T R A C T We report on a case of epilepsia partialis continua with rapid response to intravenous bolus administration of levetiracetam. A 60-year-old woman presented with continuous jerking of the right foot and hallux persisting for more than two days. She had a 9-year history of epilepsy due to a left temporoparietal oligodendroglioma with occasional focal seizures clinically presenting as speech arrest, which was treated with levetiracetam and oxcarbazepine administered orally. After hospital admission, the twitching of the foot and toe was refractory to add-on treatment with lorazepam and diazepam but stopped within 15 min after intravenous bolus administration of 2000 mg levetiracetam. This observation suggests that intravenous bolus administration of levetiracetam may be an effective therapeutic option in epilepsia partialis continua. 
Discussion
Several case series have shown levetiracetam to be an effective therapeutic option in patients with refractory status epilepticus. 8, 9 Recently, levetiracetam was approved as an intravenous formula and first reports suggest it to be highly effective in the treatment of benzodiazepine refractory status epilepticus. 10 To our best knowledge no reports exist of intravenous levetiracetam treatment in EPC, which is considered to be a rare subtype of focal status epilepticus, 11 characterized by a high resistance of the continuous focal seizures to anticonvulsive drug treatment. In our patient, application of two different benzodiazepines had not been able to control EPC. Since phenytoin could not be applied due to a known intolerance and valproate due to repeatedly elevated liver enzymes in the history, we administered an intravenous bolus of levetiracetam whereupon the EPC immediately stopped. Interestingly, our patient was pretreated with an oral dose of 1000 mg levetiracetam daily, which could not prevent the onset of EPC, although the serum level at admission had been in the range suggested for permanent oral treatment. 12 This lends support to the notion, that therapeutic ranges are a poor guide for treating seizures. Furthermore, our case shows, that an intravenous bolus of levetiracetam can be effective in focal status epilepticus like EPC despite oral pretreatment with 1000 mg daily. This is supported by findings, which consider ''supratherapeutic'' serum concentrations of antiepileptic drugs necessary for an optimal response in some patients. 13 Thus far, response to medical treatment in EPC has been largely discouraging, making anticonvulsive drug polytherapy necessary in most cases with subsequent summation of side-effects and interactions. 2, 5 In this context, our observation suggests intravenous levetiracetam to be a promising therapeutic option for treatment of EPC, as it has a rapid antiepileptic effect with low side-effects and only few interactions with other antiepileptic drugs.
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